Splice-altering TP53 missense mutations: Drivers of functional loss and therapeutic targets via RNA modulation
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 18 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE297670_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1265660 and SRA study SRP586590. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 18 sample titles: 18 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8996377 Wild type treated with AMO-control, and then DMSO
- GSM8996378 Wild type treated with AMO-control, and then Doxorubicin
- GSM8996379 AMO group, TP53 mutant (c.182A>G) treated with AMO, and then DMSO
- GSM8996380 AMO group, TP53 mutant (c.318C>G) treated with AMO, and then DMSO
- GSM8996381 AMO group, TP53 mutant (c.356C>G) treated with AMO, and then DMSO
- GSM8996382 AMO group, TP53 mutant (c.362C>A) treated with AMO, and then DMSO
- GSM8996383 AMO group, TP53 mutant (c.182A>G) treated with AMO, and then Doxorubicin
- GSM8996384 AMO group, TP53 mutant (c.318C>G) treated with AMO, and then Doxorubicin
- GSM8996385 AMO group, TP53 mutant (c.356C>G) treated with AMO, and then Doxorubicin
- GSM8996386 AMO group, TP53 mutant (c.362C>A) treated with AMO, and then Doxorubicin
- GSM8996387 Control group, TP53 mutant (c.182A>G) treated with AMO-control, and then DMSO
- GSM8996388 Control group, TP53 mutant (c.318C>G) treated with AMO-control, and then DMSO
- GSM8996389 Control group, TP53 mutant (c.356C>G) treated with AMO-control, and then DMSO
- GSM8996390 Control group, TP53 mutant (c.362C>A) treated with AMO-control, and then DMSO
- GSM8996391 Control group, TP53 mutant (c.182A>G) treated with AMO-control, and then Doxorubicin
- GSM8996392 Contorl group, TP53 mutant (c.318C>G) treated with AMO-control, and then Doxorubicin
- GSM8996393 Control group, TP53 mutant (c.356C>G) treated with AMO-control, and then Doxorubicin
- GSM8996394 Control group, TP53 mutant (c.362C>A) treated with AMO-control, and then Doxorubicin
- GSE252264 RIPK4 driven by TP53 mutations promotes resistance to PANoptosis and metastasis of CRC by phosphorylation of MTHFD1 18 samples shares tp53, mutations
- GSE300628 HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies 60 samples shares therapeutic, targets
- GSE313802 Identification of Therapeutic Targets for Low-Grade Serous Ovarian Carcinoma 28 samples shares therapeutic, targets
- GSE145057 Establishment of a human tongue cancer organoid biobank enables early diagnosis, prognosis, and identification of therapeutic targets 25 samples shares therapeutic, targets
- GSE199939 Comprehensive transcriptomic analysis of immune-related genes in diabetic foot ulcers: New insights into mechanisms and therapeutic targets 21 samples shares therapeutic, targets
- GSE244832 Multi-Modal Comparison of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease 36 samples shares therapeutic, targets
- GSE290866 Programmable mRNA Therapeutics for Controlled Epigenomic Modulation of Single and Multiplexed Gene Expression in Diverse Diseases (human data) 20 samples shares therapeutic, modulation
- GSE305560 TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia 18 samples shares tp53
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.